The HPV Vaccine is a vaccine developed to provide protection against Human Papillomavirus (HPV) infection and is recognized as an important public health tool due to its cancer-preventing potential.
- HPV: It is one of the most common sexually transmitted infections and can cause cervical, anal, penile, vaginal, vulvar, and oropharyngeal (throat) cancers, as well as genital warts.
- Mechanism: HPV vaccines contain virus-like particles (VLP) located on the outer surface of the virus that do not cause infection. When these VLPs are administered to the body, the immune system recognizes the virus and produces strong antibodies against it. These antibodies ensure the prevention of infection when the actual HPV virus is encountered.
- Prevention, Not Treatment: The vaccine does not treat an existing HPV infection or genital warts; it only prevents future infections.
Current HPV Vaccine Types and Coverage
There are two main types of HPV vaccines used and widely known today: Bivalent and Nonavalent.
| Vaccine Type | HPV Types Covered | Diseases Protected Against |
|---|---|---|
| Bivalent (HPV 16/18) | High-risk (Carcinogenic) types 16 and 18. | Particularly effective in protecting against cervical cancer. |
| Nonavalent (Gardasil 9) | Low-risk (Wart-causing) types 6 and 11. High-risk (Carcinogenic) types 16, 18, 31, 33, 45, 52, 58. | Provides protection against more than 90% of genital warts and more than 90% of HPV-related cancers. |
The nonavalent vaccine is the most frequently preferred and recommended vaccine type today due to its broad scope of protection.
Who Should Get Vaccinated and at What Age? (Male/Female)
The HPV vaccine is critically important for both women and men, and receiving it before sexual activity begins provides the highest level of protection.
- Target Age Group (Optimal): The World Health Organization (WHO) and international health organizations recommend the vaccine for all boys and girls between the ages of 9-14. In this age range, the immune response is highest, and two doses are usually sufficient.
- Catch-up Vaccination: For individuals not previously vaccinated, the vaccine is generally recommended up to age 26. For individuals between the ages of 27-45, it can be administered based on a physician's decision following an individual risk assessment.
- Dosage Protocol:
- Ages 9-14: 2 doses administered 6 to 12 months apart.
- Ages 15 and older: 3 doses to be completed within 6 months (Month 0, Month 2, and Month 6).
Benefits of the HPV Vaccine: Prevented Cancers and Warts
The vaccine protects not only the vaccinated individual but also their partner by reducing the spread of the virus in the community (herd immunity).
- In Women: Prevention of cervical cancer, vaginal and vulvar cancers, and genital warts.
- In Men: Prevention of more than 90% of penile cancer, anal cancer, and genital warts.
- In Both Sexes: Potential to reduce the risk of oropharyngeal (mouth and throat) cancers.
The vaccine is important even for individuals with a history of genital warts to protect against other HPV types they have not yet been exposed to.
Reliability and Side Effects of the HPV Vaccine
HPV vaccines are among the most studied and proven reliable vaccines, with decades of global application data.
- Reliability: Large-scale clinical trials and post-vaccination surveillance studies have shown that the vaccine has no serious long-term side effects.
- Common Side Effects: The most common side effects are similar to other vaccines and are generally mild:
- Pain, redness, or swelling at the injection site.
- Headache or mild fever.
- Fainting after vaccination (especially in adolescents due to fear of needles).
Adana and Regional Health Policies
Urology and gynecology specialists in Adana and the Çukurova Region actively provide information to both male and female patients regarding the importance of the HPV vaccine as part of sexual health counseling. Due to the high protectiveness and cancer prevention potential of the vaccine, vaccinating children and young adults in the optimal age group constitutes an important component of regional health policies.
